As of 10:59 am Eastern time, the S&P 500 was virtually flat, the Dow Jones Industrial Average was up 0.3 per cent, and the ...

The global weight loss and obesity management market is set to experience remarkable expansion in the coming decade. With new ...

Amgen shares dropped over 7% Tuesday after bone density data from an early-stage trial of its weight loss drug, MariTide, ...

Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a ...

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of ...

An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis ...

U.S. stocks are drifting near their records after the latest inflation update boosted hopes that more help for the economy ...

In this photo illustration, Amgen logo is displayed on a smartphone with a S&P ... [+] index website background. (Photo ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

Recent health news highlights include Amgen addressing bone density concerns, AstraZeneca revising its financial outlook ...

Tuesday's stock decline lopped roughly $12 billion from Amgen's market capitalization. In premarket trading Wednesday, Amgen shares rose 2.9% to $307.36. Write to Colin Kellaher at ...

(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a ...